Novo Nordisk’s Amycretin Shows Promise in Weight Loss

Published: 2025/11/25 16:26:53

Introduction

Following a setback with it’s Alzheimer’s drug semaglutide, Novo Nordisk has reported positive mid-stage trial results for amycretin, a next-generation weight-loss drug. The Phase II trial data indicates significant placebo-adjusted weight loss with both oral and subcutaneous formulations, possibly positioning amycretin as a powerful new tool in the fight against obesity and type 2 diabetes.

Understanding Amycretin: A Dual-Action Approach

Amycretin is a novel drug that differs from existing GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro). While those drugs target a single receptor, amycretin is a dual agonist. This means it activates both the GLP-1 receptor and the amylin receptor.

• GLP-1 Receptors: These receptors are found in the pancreas, brain, and gut. Activation leads to increased insulin secretion, decreased glucagon secretion, slowed gastric emptying, and reduced appetite.
• Amylin Receptors: Amylin is a hormone co-secreted with insulin.Activating amylin receptors further suppresses appetite and promotes feelings of fullness.

By targeting both receptors,amycretin aims to provide a more potent and extensive effect on weight management and metabolic control.This dual action is believed to be the key driver behind the observed weight loss results.

Phase II Trial Results: A Detailed Look

The Phase II trial involved 448 participants with type 2 diabetes. The results, released in November 2025, demonstrated the following placebo-adjusted weight loss after 36 weeks:

• Daily Oral Amycretin: 7.6% reduction in body weight
• Weekly Subcutaneous Amycretin: 11.9% reduction in body weight

These results are particularly noteworthy when compared to semaglutide, which typically achieves around 15% weight loss in clinical trials. While amycretin’s subcutaneous formulation didn’t quite reach that level, the oral formulation offers a convenient choice for patients who prefer to avoid injections. Analysts at BMO Capital Markets highlighted these findings, suggesting a strong potential for the drug.

Safety and Tolerability

The trial also assessed the safety and tolerability of amycretin. As with other GLP-1 receptor agonists, the most common side effects were gastrointestinal, including nausea, diarrhea, and vomiting. though, these side effects were generally mild to moderate and manageable. Further investigation into long-term safety will be crucial in subsequent trials.

The Competitive Landscape and Future Outlook

The weight-loss drug market is rapidly expanding,with significant demand and increasing competition. novo Nordisk already dominates the market with Wegovy and Ozempic.Eli Lilly’s tirzepatide (Zepbound) is a strong competitor. Amycretin’s potential advantages – particularly the oral formulation and the dual-agonist mechanism – could allow it to carve out a significant market share.

The next step for amycretin is Phase III clinical trials,which will involve a larger and more diverse patient population. These trials will be critical for confirming the efficacy and safety of the drug and for obtaining regulatory approval. If triumphant, amycretin could become a valuable addition to the arsenal of treatments for obesity and type 2 diabetes, offering patients more options and potentially better outcomes.

Key Takeaways

• Amycretin is a novel dual-agonist drug targeting both GLP-1 and amylin receptors.
• Phase II trial results show promising placebo-adjusted weight loss of 7.6% (oral) and 11.9% (subcutaneous) after 36 weeks.
• The oral formulation offers a convenient alternative to injectable weight-loss medications.
• Amycretin’s safety profile appears manageable, with common side effects being gastrointestinal in nature.
• Phase III trials are the next crucial step in the drug’s development.